Samil Pharmaceutical Co. Ltd. (000520.XKRX) Financials
All currency values in ₩ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | ₩207,329 | ₩210,253 | ₩219,700 | ₩196,346 | ₩179,676 | ₩134,247 |
| Cost of Revenue | ₩133,377 | ₩133,135 | ₩138,785 | ₩122,275 | ₩112,191 | ₩85,259 |
| Gross Profit | ₩73,952 | ₩77,118 | ₩80,914 | ₩74,071 | ₩67,486 | ₩48,988 |
| Total Operating Expenses | ₩102,385 | ₩99,330 | ₩80,801 | ₩67,600 | ₩63,469 | ₩48,589 |
| Operating Income | -₩28,433 | -₩22,212 | ₩113 | ₩6,471 | ₩4,017 | ₩400 |
| Non-Operating | ||||||
| Net Interest Expense | -₩8,831 | -₩8,772 | -₩5,057 | -₩3,545 | -₩4,263 | -₩6,202 |
| Income Tax Expense | -₩1,959 | -₩2,495 | ₩2,016 | -₩240 | ₩1,086 | ₩585 |
| Net Income | ||||||
| Net Income | -₩37,609 | -₩34,664 | -₩5,629 | ₩1,664 | -₩28 | -₩5,347 |
| Per Share Data | ||||||
| Revenue Per Share | ₩9,705.54 | ₩9,905.00 | ₩12,216.73 | ₩13,691.36 | ₩11,548.90 | ₩9,701.02 |
| EPS (Basic) | -₩1,767.68 | -₩1,633.00 | -₩313.00 | ₩116.00 | -₩1.82 | -₩386.36 |
| EPS (Diluted) | -₩1,767.68 | -₩1,633.00 | -₩313.00 | ₩115.00 | -₩1.82 | -₩386.36 |
| Shares Outstanding | 21.4M | 21.2M | 18.0M | 14.3M | 15.6M | 13.8M |
| Dividends Per Share | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩72.73 |
Samil Pharmaceutical Co. (000520.XKRX) financials: revenue, profit and margins
Samil Pharmaceutical Co. (000520.XKRX) generated about KRW 207.3 billion in revenue and -KRW 37.6 billion in net income (a -18.1% net margin) over the trailing twelve months, growing at roughly 11.9% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Samil Pharmaceutical Co.'s (000520.XKRX) revenue?+
Samil Pharmaceutical Co. generated about KRW 207.3 billion in revenue over the trailing twelve months. Revenue has grown at roughly 11.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Samil Pharmaceutical Co. profitable?+
Samil Pharmaceutical Co. reported about -KRW 37.6 billion in net loss over the trailing twelve months, a net margin of roughly -18.1%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Samil Pharmaceutical Co.'s profit margins?+
Samil Pharmaceutical Co. runs a gross margin of about 35.7%, an operating margin of about -13.7%, a net margin of about -18.1%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Samil Pharmaceutical Co. growing?+
Samil Pharmaceutical Co.'s revenue has compounded at roughly 11.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside 000520.XKRX's margins and free cash flow. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.